US Could Save Nearly $1 Billion With Pembrolizumab Dosing Change

In this video, Daniel A. Goldstein, MD, of the Davidoff Cancer Center in Israel, discusses a study that found that a change to weight-based pembrolizumab dosing in first-line PD-L1–positive non–small-cell lung cancer could save nearly $1 billion in US healthcare expenditures.

Goldstein presented results of the study (abstract 9013) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.